Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764258 | 0.77 | TSPO (0.43) | TSPO | |
| SCHEMBL414152 | 0.77 | TSPO (0.69) | TSPO | |
| SCHEMBL414618 | 0.76 | TSPO (0.52) | TSPO | |
| SCHEMBL4263164 | 0.73 | HTR6 (0.55) | TSPO | |
| SCHEMBL6983411 | 0.70 | HTR6 (0.45) | TSPO | |
| SCHEMBL11838102 | 0.70 | PTGS2 (0.49) | NPSR1 | |
| SCHEMBL415476 | 0.69 | TSPO (0.75) | TSPO | |
| SCHEMBL30106119 | 0.69 | TSPO (0.75) | TSPO | |
| SCHEMBL11839021 | 0.69 | TSPO (0.41) | TSPO | |
| SCHEMBL6697892 | 0.68 | HTR6 (0.43) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | GE HEALTHCARE LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| US-20150335766-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20150335766-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| WO-2014083113-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335766-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | IDO1, IDO2, TPH1 | TSPO 3643/4885NPSR1 619/4885 |
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | IDO1, IDO2, TPH1 | TSPO 3643/4885NPSR1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.